Clear Street’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Clear Street’s Portfolio DMAA Stock Details DMAA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.65M	Buy	382,440 +28,392	+8%	+$301K	﹤0.01%	317
2026 Q1	$1.3M	Buy	354,048 +28,075	+9%	+$293K	0.01%	305
2025 Q4	$996K	Buy	325,973 +116,407	+56%	+$1.2M	﹤0.01%	294
2025 Q3	$2.15M	Buy	209,566 +96,951	+86%	+$995K	0.01%	170
2025 Q2	$1.15M	Buy	+112,615	New	+$1.14M	﹤0.01%	114

Other funds holding DMAA

Karpus Investment Management Pittsford, New York $3.34B AUM 3.39% 1-Year Est. Return

Mizuho Securities USA New York $6.3B AUM 30.7% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $14.9B AUM 3.61% 1-Year Est. Return

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

First Trust Capital Management Chicago, Illinois $2.08B AUM 59.2% 1-Year Est. Return

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 22.91% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Clear Street's DMAA Position: Q2 2026 in Review

Clear Street increased its Drugs Made In America Acquisition Corp (DMAA) stake by 8% in Q2 2026, buying an estimated $301K and bringing the position to 382,440 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #317.

Clear Street first reported a position in DMAA in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.15M in Q3 2025. 23 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

Clear Street held 382,440 shares of Drugs Made In America Acquisition Corp worth $1.65M as of Q2 2026.
Clear Street bought 28,392 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $301K.
Drugs Made In America Acquisition Corp made up ﹤0.01% of Clear Street's portfolio in Q2 2026, its #317 holding.
Clear Street first reported a position in Drugs Made In America Acquisition Corp in Q2 2025 and has held it in 5 quarters since.
Clear Street's Drugs Made In America Acquisition Corp position peaked at $2.15M in Q3 2025.
23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Clear Street's 13F filing for Q2 2026, filed 12 Aug 2026.